OncoMatch/Clinical Trials/NCT07227298
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Is NCT07227298 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including PF-08634404 and Sigvotatug Vedotin for advanced/metastatic non-small cell lung cancer.
Treatment: PF-08634404 · Sigvotatug Vedotin · Combination Agent 1 — This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (status available)
PD-L1 status available
Required: PD-L1 (CD274) overexpression (TPS ≥ 1%)
Part B only: PD-L1 ≥ TPS 1%
Excluded: EGFR any mutation
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: ALK fusion
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: ROS1 fusion
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: NTRK1 fusion
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: NTRK2 fusion
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: NTRK3 fusion
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: BRAF any mutation
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Excluded: MET any mutation
Participants with known AGAs including EGFR, ALK and ROS1, NTRK, BRAF, and MET
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-tumor therapy
Previous systemic anti-tumor therapy for locally advanced, unresectable, or metastatic NSCLC
Cannot have received: immunotherapy
Exception: (neo)adjuvant anti-PD-(L)1 allowed
Previous treatment with immunotherapy (exception is (neo)adjuvant anti-PD-(L)1)
Cannot have received: antibody-drug conjugate
ADCs containing MMAE payload
Cannot have received: systemic anti-angiogenic therapy
systemic anti-angiogenic therapy
Cannot have received: radiation therapy
Exception: prior radiotherapy to the lung within 6 months of first dose of study intervention
prior radiotherapy to the lung within 6 months of first dose of study intervention
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mid Florida Hematology and Oncology Center · Orange City, Florida
- Oncology Associates of Oregon, P.C · Eugene, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify